Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus inhaled - OrphAI Therapeutics

Next Previous
Drug Profile

Sirolimus inhaled - OrphAI Therapeutics

Alternative Names: LAM 001; Rapamycin inhaled - OrphAI Therapeutics

Latest Information Update: 04 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LAM Therapeutics
  • Developer OrphAI Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphangioleiomyomatosis; Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bronchiolitis obliterans; Pulmonary arterial hypertension; Pulmonary sarcoidosis
  • Discontinued Lymphangioleiomyomatosis

Most Recent Events

  • 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics
  • 18 Aug 2023 AI Therapeutics initiates enrolment in a phase II trial for Bronchiolitis Obliterans (Newly diagnosed) in USA (Inhalation)
  • 03 Apr 2023 Phase-II clinical trials in Pulmonary arterial hypertension (Adjunctive treatment) in USA (Inhalation) (NCT05798923)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top